Curis (CRIS) Non-Current Assets (2010 - 2026)
Curis' (CRIS) quarterly Non-Current Assets came in at $12.2 million in Q2 2026, down 17.34% on a YoY basis from $14.8 million in Q2 2025, and down 6.34% quarter-over-quarter from $13.1 million in Q1 2026.
Analysis
Curis (CRIS) Non-Current Assets (2010 - 2026) Analysis & Trends
Curis (CRIS) has reported Non-Current Assets for 17 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets fell 17.34% year-over-year to $12.2 million; the trailing twelve-month figure through Jun 2026 stood at $52.1 million (down 12.79% YoY), and the FY2025 full-year result was $13.1 million, down 12.29% from the prior year.
- Non-Current Assets fell to $12.2 million in Q2 2026 per CRIS's latest filing, from $13.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $17.1 million in Q3 2022 and bottomed at $12.2 million in Q2 2026.
- Historically, Non-Current Assets has averaged $15.2 million across 5 years, with a median of $15.5 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 58.1% in 2022, then grew 13.25% in 2023.
- Over 5 years, Non-Current Assets stood at $16.7 million in 2022, then fell by 2.12% to $16.4 million in 2023, then retreated by 9.12% to $14.9 million in 2024, then fell by 12.29% to $13.1 million in 2025, then decreased by 6.17% to $12.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $12.2 million, $13.1 million, and $13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Curis | 2.64 Mn | -2.97 Mn | - | 12.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.25 Mn |
| Mar 31, 2026 | 13.08 Mn |
| Dec 31, 2025 | 13.05 Mn |
| Sep 30, 2025 | 13.73 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Mar 31, 2025 | 14.52 Mn |
| Dec 31, 2024 | 14.88 Mn |
| Sep 30, 2024 | 15.54 Mn |
| Jun 30, 2024 | 15.89 Mn |
| Mar 31, 2024 | 15.96 Mn |
| Dec 31, 2023 | 16.37 Mn |
| Sep 30, 2023 | 16.55 Mn |
| Jun 30, 2023 | 16.46 Mn |
| Mar 31, 2023 | 16.53 Mn |
| Dec 31, 2022 | 16.73 Mn |
| Sep 30, 2022 | 17.14 Mn |
| Jun 30, 2022 | 15.44 Mn |
| Mar 31, 2022 | 14.60 Mn |
| Dec 31, 2021 | 39.93 Mn |
| Sep 30, 2021 | 37.14 Mn |